
浏览全部资源
扫码关注微信
1.江西科技师范大学药学院,南昌 330013
2.江西中医药大学现代中药制剂教育部重点实验室,南昌 330004
硕士研究生。研究方向:中药药理。E-mail:1550142502@qq.com
副教授,硕士生导师,博士。研究方向:中药药理。 E-mail:tangxilan1983@163.com
收稿日期:2024-08-26,
修回日期:2025-02-17,
录用日期:2025-01-16,
纸质出版日期:2025-03-15
移动端阅览
李意婷,董伟,梁新丽,等.基于转录组学探讨欧前胡素改善乳腺癌多柔比星耐药的机制[J].中国药房,2025,36(05):529-534.
LI Yiting,DONG Wei,LIANG Xinli,et al.Mechanism of imperatorin in ameliorating doxorubicin resistance of breast cancer based on transcriptomics[J].ZHONGGUO YAOFANG,2025,36(05):529-534.
李意婷,董伟,梁新丽,等.基于转录组学探讨欧前胡素改善乳腺癌多柔比星耐药的机制[J].中国药房,2025,36(05):529-534. DOI: 10.6039/j.issn.1001-0408.2025.05.04.
LI Yiting,DONG Wei,LIANG Xinli,et al.Mechanism of imperatorin in ameliorating doxorubicin resistance of breast cancer based on transcriptomics[J].ZHONGGUO YAOFANG,2025,36(05):529-534. DOI: 10.6039/j.issn.1001-0408.2025.05.04.
目的
2
研究欧前胡素(IMP)对乳腺癌多柔比星(DOX)耐药的逆转作用及可能机制。
方法
2
采用MTT法考察IMP最大无毒质量浓度(100 μg/mL)与DOX不同质量浓度(12.5、25、50、75、100 μg/mL)联用对MCF-7/DOX细胞增殖的影响;将MCF-7/DOX细胞分为空白对照组(1‰二甲基亚砜)、DOX组(50 μg/mL)、IMP+DOX组(100 μg/mL IMP+50 μg/mL DOX)和IMP组(100 μg/mL),检测各组细胞中多药耐药蛋白1(MDR1)、多药耐药相关蛋白1的mRNA及其蛋白表达水平;采用转录组测序技术及基因本体(GO)富集分析、京都基因与基因组百科全书(KEGG)通路富集分析筛选IMP改善乳腺癌DOX耐药相关的通路和靶点,并进行验证。
结果
2
与单用DOX比较,IMP与DOX联用后,DOX对MCF-7/DOX细胞的半数抑制浓度从81.965 μg/mL下降至43.170 μg/mL,耐药逆转倍数为1.90;且联用可显著下调MDR1的mRNA表达(
P
<0.05)。GO富集分析和KEGG通路富集分析结果显示,IMP逆转乳腺癌DOX耐药主要与调节解毒、多生物过程、细胞杀伤等生物过程有关,主要涉及p53信号通路,关键靶点为组成型光形态建成蛋白1(COP1)、细胞周期蛋白E1(CCNE1)、生长停滞和DNA损伤诱导蛋白45A(GADD45A)及GADD45B。验证实验结果显示,与DOX组比较,IMP+DOX组细胞中COP1的mRNA表达有上调趋势,但CCNE1、GADD45A及GADD45B的mRNA表达均显著下调(
P
<0.05)。
结论
2
IMP逆转乳腺癌DOX耐药的作用可能与调控p53信号通路中COP1、CCNE1、GADD45A及GADD45B的表达有关。
OBJECTIVE
2
To investigate the ameliorative effect and potential mechanism of imperatorin (IMP) on doxorubicin (DOX) resistance in breast cancer.
METHODS
2
The effects of maximum non-toxic concentration (100 μg/mL) of IMP combined with different concentrations of DOX (12.5, 25, 50, 75, 100 μg/mL) on the proliferation of MCF-7/DOX cells were determined by MTT method. MCF-7/DOX cells were divided into blank control group (1‰ dimethyl sulfoxide), DOX group (50 μg/mL), IMP+DOX group (100 μg/mL IMP+50 μg/mL DOX) and IMP group (100 μg/mL). mRNA and protein expressions of multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 1 in each group were measured. The relevant pathways and targets involved in the improvement of DOX resistance in breast cancer cells by IMP were screened and validated by using transcriptome sequencing technology, along with gene ontology (GO) enrichment analyses and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses.
RESULTS
2
Compared with DOX alone, the combination of IMP and DOX reduced the half inhibitory concentration of DOX on MCF-7/DOX cells from 81.965 μg/mL to 43.170 μg/mL, the reverse fold was 1.90, and the mRNA expression of MDR1 was significantly down-regulated (
P
<0.05). The results of GO enrichment analyses and KEGG pathway enrichment analyses indicated that the reversal of DOX resistance in breast cancer by IMP was mainly associated with the regulation of biological processes such as detoxification, multiple biological processes, and cell killing. The main pathway involved was the p53 signaling pathway, and the key targets mainly included constitutively photomorphogenic protein 1 (COP1), cyclin E1 (CCNE1), growth arrest and DNA damage-inducible protein 45A (GADD45A) and GADD45B. The results of the verification experiments showed that compared with DOX group, there was a trend of up-regulation of COP1 mRNA, and significant down-regulation of CCNE1, GADD45A, and GADD45B mRNA expression in IMP+DOX group (
P
<0.05).
CONCLUSIONS
2
The effect of IMP in ameliorating DOX resistance in breast cancer is related to its regulation of COP1, CCNE1, GADD45A and GADD45B targets in the p53 signaling pathway.
SIEGEL R L , GIAQUINTO A N , JEMAL A . Cancer sta- tistics,2024 [J ] . CA A Cancer J Clinicians , 2024 , 74 ( 1 ): 12 - 49 .
AL-MALKY H S , AL HARTHI S E , OSMAN A M . Major obstacles to doxorubicin therapy:cardiotoxicity and drug resistance [J ] . J Oncol Pharm Pract , 2020 , 26 ( 2 ): 434 - 444 .
NASSER M I , ZHU S J , HU H Y , et al . Effects of imperatorin in the cardiovascular system and cancer [J ] . Biomed Pharmacother , 2019 , 120 : 109401 .
WU C P , MURAKAMI M , LI Y C , et al . Imperatorin restores chemosensitivity of multidrug-resistant cancer cells by antagonizing ABCG2-mediated drug transport [J ] . Pharmaceuticals (Basel) , 2023 , 16 ( 11 ): 1595 .
LIANG X L , JI M M , LIAO Z G , et al . Chemosensitizing effect and mechanism of imperatorin on the anti-tumor activity of doxorubicin in tumor cells and transplantation tumor model [J ] . Korean J Physiol Pharmacol , 2022 , 26 ( 3 ): 145 - 155 .
MA M J , SHI Y H , LIU Z D , et al . N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance [J ] . Oncogene , 2024 , 43 ( 31 ): 2405 - 2420 .
HU J J , XU C L , CHENG B H , et al . Imperatorin acts as a cisplatin sensitizer via downregulating Mcl-1 expression in HCC chemotherapy [J ] . Tumour Biol , 2016 , 37 ( 1 ): 331 - 339 .
YOU C X , YANG Y , GAO B L . Imperatorin targets MCL-1 to sensitize CD133 + lung cancer cells to γδ-T cell-mediated cytotoxicity [J ] . Cell Physiol Biochem , 2018 , 49 ( 1 ): 235 - 244 .
汤喜兰 , 李洪铭 , 梁新丽 , 等 . 苦瓜素Ⅰ抑制乳腺癌MCF-7/DOX细胞多柔比星耐药的研究 [J ] . 中国医院药学杂志 , 2021 , 41 ( 13 ): 1293 - 1298 .
TANG X L , LI H M , LIANG X L , et al . Suppression of momordicin Ⅰ on the resistance of breast cancer MCF-7/DOX cells to doxorubicin [J ] . Chin J Hosp Pharm , 2021 , 41 ( 13 ): 1293 - 1298 .
谭睿陟 , 钟霞 , 王丽 , 等 . 蛭龙活血通瘀胶囊对小鼠脑出血及长链非编码RNA和靶基因的影响 [J ] . 中国药房 , 2022 , 33 ( 12 ): 1421 - 1429 .
TAN R Z , ZHONG X , WANG L , et al . Effects of Zhilong huoxue tongyu capsules on intracerebral hemorrhage, LncRNA and target genes in mice [J ] . China Pharm , 2022 , 33 ( 12 ): 1421 - 1429 .
ALKETBI L , AL-ALI A , TALAAT I M , et al . The role of ATP-binding cassette subfamily A in colorectal cancer progression and resistance [J ] . Int J Mol Sci , 2023 , 24 ( 2 ): 1344 .
吴杰 , 叶娟 , 曾智 , 等 . 中药单体对阿霉素增效减毒作用研究进展 [J ] . 中医药学报 , 2021 , 49 ( 9 ): 111 - 120 .
WU J , YE J , ZENG Z , et al . Research progress on synergy and attenuation of adriamycin by Chinese medicine monomer [J ] . Acta Chin Med Pharmacol , 2021 , 49 ( 9 ): 111 - 120 .
HUANG J . Current developments of targeting the p53 signaling pathway for cancer treatment [J ] . Pharmacol Ther , 2021 , 220 : 107720 .
ZHENG Y M , LU A X , SHEN J Z , et al . Imperatorin exhibits anticancer activities in human colon cancer cells via the caspase cascade [J ] . Oncol Rep , 2016 , 35 ( 4 ): 1995 - 2002 .
TANG S C , LION Q , PEULEN O , et al . The E3 ligase COP1 promotes ERα signaling and suppresses EMT in breast cancer [J ] . Oncogene , 2022 , 41 ( 2 ): 173 - 190 .
CAI Z J , WANG J R , LI Y D , et al . Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors [J ] . Sci China Life Sci , 2023 , 66 ( 1 ): 94 - 109 .
刘雪妮 , 王超 , 程艳红 , 等 . 慢病毒载体上调GADD45α增强伊马替尼耐药株K562IR细胞的药物敏感性 [J ] . 安徽医科大学学报 , 2021 , 56 ( 12 ): 1920 - 1924 .
LIU X N , WANG C , CHENG Y H , et al . Upregulation of GADD45α by lentivirus vector enhances the drug-sensiti- vity of imatinib-resistant K562IR cells [J ] . Acta Univ Med Anhui , 2021 , 56 ( 12 ): 1920 - 1924 .
WANG Q , WU W H , GAO Z , et al . GADD45B is a potential diagnostic and therapeutic target gene in chemotherapy-resistant prostate cancer [J ] . Front Cell Dev Biol , 2021 , 9 : 716501 .
LIU J , JIANG G Q , MAO P , et al . Down-regulation of GADD45A enhances chemosensitivity in melanoma [J ] . Sci Rep , 2018 , 8 ( 1 ): 4111 .
胡皓 , 阙凯琳 , 彭昊 , 等 . 下调生长阻滞和DNA损伤诱导蛋白45β表达对PC9肺腺癌细胞的影响 [J ] . 中南大学学报(医学版) , 2018 , 43 ( 11 ): 1209 - 1215 .
HU H , QUE K L , PENG H , et al . Effect of down-regulation of growth arrest and DNA damage inducible protein 45β on PC9 lung adenocarcinoma cells [J ] . J Cent South Univ Med Sci , 2018 , 43 ( 11 ): 1209 - 1215 .
0
浏览量
26
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
公网安备50010302001817